Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc.DNA · Entity 5530 | See remarks | May 20, 2025 | May 22, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ginkgo Bioworks Holdings, Inc.
Report date May 20, 2025 · Filed May 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 46,226 |
Ending reported balance
After 2025-05-21 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-05-20 · Exercise / conversion · Acquired 454 · Balance 45,907 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 2 · 2025-05-20 · Exercise / conversion · Acquired 453 · Balance 46,360 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 3 · 2025-05-20 · Exercise / conversion · Acquired 572 · Balance 46,932 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 4 · 2025-05-21 · Sale · Disposed 706 · Balance 46,226 F2: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,614 |
Reported balance
After 2025-05-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-05-20 · Exercise / conversion · Disposed 454 · Balance 3,614 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,970 |
Reported balance
After 2025-05-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-05-20 · Exercise / conversion · Disposed 453 · Balance 9,970 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3: The RSUs vest in 48 equal monthly installments, which began on April 1, 2023. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 19,488 |
Reported balance
After 2025-05-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-05-20 · Exercise / conversion · Disposed 572 · Balance 19,488 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4: The RSUs vest in 48 equal monthly installments, which began on April 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.
F3: The RSUs vest in 48 equal monthly installments, which began on April 1, 2023.
F4: The RSUs vest in 48 equal monthly installments, which began on April 1, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2023 Filed May 4, 2023 20:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 65,281 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-014598 · form4.xml · derivative · entry 5 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,431,044 Underlying: Class A Common Stock · 65,281 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · kind: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| May 01, 2023 Filed May 4, 2023 20:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 1,637 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-014598 · form4.xml · nonDerivative · entry 3 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 661,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| May 01, 2023 Filed May 4, 2023 20:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 18,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-014598 · form4.xml · nonDerivative · entry 2 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 659,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| May 01, 2023 Filed May 4, 2023 20:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 65,281 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-014598 · form4.xml · nonDerivative · entry 1 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 641,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 17:03 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 740 | $1.33 | $986.42 |
DisclosureSEC source: 0001127602-23-012816 · form4.xml · nonDerivative · entry 2 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 576,254 F3 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| April 06, 2023 Filed Apr 11, 2023 17:03 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 1,636 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-012816 · form4.xml · derivative · entry 3 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 648,317 Underlying: Class A Common Stock · 1,636 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F4 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions. Read SEC document |
| April 06, 2023 Filed Apr 11, 2023 17:03 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 1,636 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-012816 · form4.xml · nonDerivative · entry 1 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 576,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 18:36 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 38,787 | $1.27 | $49,220.70 |
DisclosureSEC source: 0001127602-23-012623 · form4.xml · nonDerivative · entry 3 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,358 F3 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 18:36 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 18,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-012623 · form4.xml · derivative · entry 5 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 851,875 Underlying: Class A Common Stock · 18,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · kind: Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: The RSUs vest in 48 equal monthly installments, which began on April 1, 2023. F4 · derivative.expiration_date: The RSUs vest in 48 equal monthly installments, which began on April 1, 2023. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 18:36 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 65,284 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-012623 · form4.xml · derivative · entry 4 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,496,325 Underlying: Class A Common Stock · 65,284 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,284 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,284 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,284 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,284 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,284 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 18:36 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 18,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-012623 · form4.xml · nonDerivative · entry 2 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 614,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 18:36 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 65,284 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-012623 · form4.xml · nonDerivative · entry 1 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 596,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,284 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,284 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 17:34 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 29,762 | $1.31 | $39,107.27 |
DisclosureSEC source: 0001127602-23-010470 · form4.xml · nonDerivative · entry 2 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530,736 F2 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 17:34 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 65,281 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-010470 · form4.xml · derivative · entry 3 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,561,609 Underlying: Class A Common Stock · 65,281 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,281 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,281 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,281 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,281 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,281 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 17:34 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 65,281 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-010470 · form4.xml · nonDerivative · entry 1 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,281 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,281 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 1,635 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-008825 · form4.xml · derivative · entry 2 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,953 Underlying: Class A Common Stock · 1,635 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 1,635 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-008825 · form4.xml · nonDerivative · entry 1 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| March 01, 2023 Filed Mar 10, 2023 16:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantRestricted Stock Units · Derivative | 870,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-009748 · form4.xml · derivative · entry 1 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 870,000 Underlying: Class A Common Stock · 870,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: The RSUs vest in 48 equal monthly installments beginning on April 1, 2023. F2 · derivative.expiration_date: The RSUs vest in 48 equal monthly installments beginning on April 1, 2023. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 17:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 27,889 | $2.15 | $59,933.46 |
DisclosureSEC source: 0001127602-23-003403 · form4.xml · nonDerivative · entry 3 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 493,582 F4 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 1,638 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003403 · form4.xml · derivative · entry 5 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,588 Underlying: Class A Common Stock · 1,638 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 65,284 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003403 · form4.xml · derivative · entry 4 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,626,890 Underlying: Class A Common Stock · 65,284 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,284 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,284 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,284 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,284 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,284 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 1,638 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003403 · form4.xml · nonDerivative · entry 2 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 65,284 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003403 · form4.xml · nonDerivative · entry 1 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 519,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,284 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 65,284 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 18:28 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 34,588 | $1.56 | $53,818.93 |
DisclosureSEC source: 0001127602-23-001110 · form4.xml · nonDerivative · entry 3 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,549 F4 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 18:28 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 1,635 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-001110 · form4.xml · derivative · entry 5 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,226 Underlying: Class A Common Stock · 1,635 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 18:28 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 66,947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-001110 · form4.xml · derivative · entry 4 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,692,174 Underlying: Class A Common Stock · 66,947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 66,947 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 66,947 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 66,947 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 66,947 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 66,947 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 18:28 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 1,635 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-001110 · form4.xml · nonDerivative · entry 2 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 489,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 18:28 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 66,947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-001110 · form4.xml · nonDerivative · entry 1 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 66,947 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 66,947 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 21:07 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 30,102 | $1.94 | $58,488.19 |
DisclosureSEC source: 0000899243-22-037722 · doc4.xml · nonDerivative · entry 3 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,555 F4 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of securities. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:07 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 1,634 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-037722 · doc4.xml · derivative · entry 5 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 654,861 Underlying: Class A Common Stock · 1,634 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 64,949 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 64,949 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:07 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 64,949 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-037722 · doc4.xml · derivative · entry 4 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,759,121 Underlying: Class A Common Stock · 64,949 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 64,949 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 64,949 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 64,949 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 64,949 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 64,949 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:07 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 1,634 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-037722 · doc4.xml · nonDerivative · entry 2 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:07 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 64,949 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-037722 · doc4.xml · nonDerivative · entry 1 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 64,949 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 64,949 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 21:45 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 30,604 | $2.65 | $80,947.58 |
DisclosureSEC source: 0000899243-22-035329 · doc4.xml · nonDerivative · entry 3 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,074 F4 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of securities. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| November 01, 2022 Filed Nov 7, 2022 21:45 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 1,638 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035329 · doc4.xml · derivative · entry 5 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 656,495 Underlying: Class A Common Stock · 1,638 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 64,951 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 64,951 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions. Read SEC document |
| November 01, 2022 Filed Nov 7, 2022 21:45 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 64,951 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035329 · doc4.xml · derivative · entry 4 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,824,070 Underlying: Class A Common Stock · 64,951 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 64,951 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 64,951 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 64,951 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 64,951 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 64,951 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| November 01, 2022 Filed Nov 7, 2022 21:45 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 1,638 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035329 · doc4.xml · nonDerivative · entry 2 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| November 01, 2022 Filed Nov 7, 2022 21:45 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 64,951 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035329 · doc4.xml · nonDerivative · entry 1 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 64,951 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 64,951 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 20:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 279,255 | $3.25 | $907,578.75 |
DisclosureSEC source: 0000899243-22-033322 · doc4.xml · nonDerivative · entry 2 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,089 F2 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 06, 2022 Filed Nov 7, 2022 21:50 UTC Amendment | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 279,255 | $3.25 | $907,578.75 |
DisclosureSEC source: 0000899243-22-035333 · doc4a.xml · nonDerivative · entry 2 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,089 F2 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 20:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 618,242 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033322 · doc4.xml · derivative · entry 3 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,891 Underlying: Class A Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · derivative.underlying_shares: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F4 · balance_after: Excludes restricted stock units, which were previously reported as shares of Class B common stock on the Form 4 filed by the reporting person on March 14, 2022. Because the Issuer has the ability to settle such restricted stock units with shares of Class A common stock or cash upon vesting, restricted stock units will be reported separately from shares of Class B Common Stock in future reports. Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 20:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 618,242 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033322 · doc4.xml · nonDerivative · entry 1 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 627,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F1 · price: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. Read SEC document |
| October 05, 2022 Filed Nov 7, 2022 21:50 UTC Amendment | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 618,242 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035333 · doc4a.xml · derivative · entry 3 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,899,021 Underlying: Class A Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the conversion of shares of Restricted Stock Units ("RSUs") to Class A Common Stock. On October 5, 2022, the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for 618,242 vested RSUs. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · kind: Represents the conversion of shares of Restricted Stock Units ("RSUs") to Class A Common Stock. On October 5, 2022, the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for 618,242 vested RSUs. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents the conversion of shares of Restricted Stock Units ("RSUs") to Class A Common Stock. On October 5, 2022, the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for 618,242 vested RSUs. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.exercise_date: Represents the conversion of shares of Restricted Stock Units ("RSUs") to Class A Common Stock. On October 5, 2022, the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for 618,242 vested RSUs. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.expiration_date: Represents the conversion of shares of Restricted Stock Units ("RSUs") to Class A Common Stock. On October 5, 2022, the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for 618,242 vested RSUs. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.underlying_shares: Represents the conversion of shares of Restricted Stock Units ("RSUs") to Class A Common Stock. On October 5, 2022, the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for 618,242 vested RSUs. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · balance_after: Represents the conversion of shares of Restricted Stock Units ("RSUs") to Class A Common Stock. On October 5, 2022, the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for 618,242 vested RSUs. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · balance_after: On March 14, 2022, the Reporting Person filed a Form 4 that reported RSUs on a consolidated basis with holdings of Class B Common Stock. Because the Issuer has the ability to settle such RSUs with shares of Class A Common Stock or cash upon vesting, RSUs will be reported separately from shares of Class B Common Stock in future reports. In addition to the RSUs reported herein, the Reporting Person beneficially owns 658,133 shares of Class B Common Stock, which includes shares of Class B Common Stock that are subject to vesting conditions. Read SEC document |
| October 05, 2022 Filed Nov 7, 2022 21:50 UTC Amendment | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 618,242 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035333 · doc4a.xml · nonDerivative · entry 1 Dmytruk Mark E. · CIK 0001873507 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 627,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of shares of Restricted Stock Units ("RSUs") to Class A Common Stock. On October 5, 2022, the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for 618,242 vested RSUs. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents the conversion of shares of Restricted Stock Units ("RSUs") to Class A Common Stock. On October 5, 2022, the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for 618,242 vested RSUs. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 22:00 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 7,259 | $3.12 | $22,659.69 |
DisclosureSEC source: 0000899243-22-032862 · doc4.xml · nonDerivative · entry 2 Dmytruk Mark E. · CIK 0001873507 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,102 F3 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of equity securities of the Issuer. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 22:00 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 16,361 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032862 · doc4.xml · derivative · entry 3 Dmytruk Mark E. · CIK 0001873507 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658,133 Underlying: Class A Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.underlying_shares: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F4 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 22:00 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 16,361 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032862 · doc4.xml · nonDerivative · entry 1 Dmytruk Mark E. · CIK 0001873507 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 21:33 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantClass B Common Stock · Derivative | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-010986 · doc4.xml · derivative · entry 3 Dmytruk Mark E. · CIK 0001873507 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,181,757 Underlying: Class A Common Stock · 500,000 shares Expires not disclosed F1 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F4 · derivative.exercise_date: Represents an award of restricted stock units covering Class B Common Stock, which vests in 48 equal monthly installments following the vesting commencement date of March 1, 2022. F4 · derivative.expiration_date: Represents an award of restricted stock units covering Class B Common Stock, which vests in 48 equal monthly installments following the vesting commencement date of March 1, 2022. F5 · balance_after: Includes 40,000 restricted stock units covering Class B Common Stock that were previously reported as Restricted Stock Units on the Form 4 filed by the reporting person on January 26, 2022. The reporting person intends to report such restricted stock units on a consolidated basis with his holdings of the underlying Class B Common Stock in future reports. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:33 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Tax withholdingClass B Common Stock · Derivative | 289,898 | $3.37 | $976,956.26 |
DisclosureSEC source: 0000899243-22-010986 · doc4.xml · derivative · entry 2 Dmytruk Mark E. · CIK 0001873507 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,641,757 Underlying: Class A Common Stock · 289,898 shares Expires not disclosed F1 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · kind: Represents shares withheld by the Issuer to satisfy the reporting person's tax withholding obligations. Not a market sale. F2 · derivative.exercise_date: The reporting person was previously granted awards of restricted stock units covering Class B Common Stock, which vest based upon the Issuer's achievement of an event condition (i.e., an underwritten initial public offering or a change in control), subject to additional time based vesting conditions in accordance with the terms of the award. On March 10, 2022, the Compensation Committee of the Issuer's Board of Directors, after consideration of the completion of the initial business combination, modified the event condition, resulting in the immediate vesting of 650,295 restricted stock units for which the time based vesting requirements had been satisfied as of December 31, 2021 and the issuance of a corresponding number of shares of Class B Common Stock. The remaining restricted stock units covering shares of Class B Common Stock will continue to vest in accordance with the terms of the award. F2 · derivative.expiration_date: The reporting person was previously granted awards of restricted stock units covering Class B Common Stock, which vest based upon the Issuer's achievement of an event condition (i.e., an underwritten initial public offering or a change in control), subject to additional time based vesting conditions in accordance with the terms of the award. On March 10, 2022, the Compensation Committee of the Issuer's Board of Directors, after consideration of the completion of the initial business combination, modified the event condition, resulting in the immediate vesting of 650,295 restricted stock units for which the time based vesting requirements had been satisfied as of December 31, 2021 and the issuance of a corresponding number of shares of Class B Common Stock. The remaining restricted stock units covering shares of Class B Common Stock will continue to vest in accordance with the terms of the award. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:33 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantClass B Common Stock · Derivative | 2,617,558 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-010986 · doc4.xml · derivative · entry 1 Dmytruk Mark E. · CIK 0001873507 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,931,655 Underlying: Class A Common Stock · 2,617,558 shares Expires not disclosed F1 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · shares: The reporting person was previously granted awards of restricted stock units covering Class B Common Stock, which vest based upon the Issuer's achievement of an event condition (i.e., an underwritten initial public offering or a change in control), subject to additional time based vesting conditions in accordance with the terms of the award. On March 10, 2022, the Compensation Committee of the Issuer's Board of Directors, after consideration of the completion of the initial business combination, modified the event condition, resulting in the immediate vesting of 650,295 restricted stock units for which the time based vesting requirements had been satisfied as of December 31, 2021 and the issuance of a corresponding number of shares of Class B Common Stock. The remaining restricted stock units covering shares of Class B Common Stock will continue to vest in accordance with the terms of the award. F2 · derivative.exercise_date: The reporting person was previously granted awards of restricted stock units covering Class B Common Stock, which vest based upon the Issuer's achievement of an event condition (i.e., an underwritten initial public offering or a change in control), subject to additional time based vesting conditions in accordance with the terms of the award. On March 10, 2022, the Compensation Committee of the Issuer's Board of Directors, after consideration of the completion of the initial business combination, modified the event condition, resulting in the immediate vesting of 650,295 restricted stock units for which the time based vesting requirements had been satisfied as of December 31, 2021 and the issuance of a corresponding number of shares of Class B Common Stock. The remaining restricted stock units covering shares of Class B Common Stock will continue to vest in accordance with the terms of the award. F2 · derivative.expiration_date: The reporting person was previously granted awards of restricted stock units covering Class B Common Stock, which vest based upon the Issuer's achievement of an event condition (i.e., an underwritten initial public offering or a change in control), subject to additional time based vesting conditions in accordance with the terms of the award. On March 10, 2022, the Compensation Committee of the Issuer's Board of Directors, after consideration of the completion of the initial business combination, modified the event condition, resulting in the immediate vesting of 650,295 restricted stock units for which the time based vesting requirements had been satisfied as of December 31, 2021 and the issuance of a corresponding number of shares of Class B Common Stock. The remaining restricted stock units covering shares of Class B Common Stock will continue to vest in accordance with the terms of the award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.